Wednesday, September 15, 2021 at 10am EDTDrug manufacturing demands and increased regulatory oversight are prompting pharmaceutical manufacturers to consider new processes for oral solid dose and aseptically processed drugs. A cross-section of industry experts will offer insight on emerging trends, technologies, and processes in this Technology Forum.
Wednesday, September 8, 2021 at 8am EDT| 5am PDT| 1pm BST| 2pm CEST AI has opened up an enormous amount of possibilities for biomedical and life sciences organizations to use growing volumes of data to accelerate and improve upon critical processes that can speed time to value and improve patient outcomes. Learn how next generation AI is revolutionizing how these organizations can deliver innovation and value to patients and overcome the constraints of legacy technology, easier and faster than ever before.
Thursday, September 2, 2021 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Tuesday August 31, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CESTEfficiency for validation, changes to traditional practices to be more efficient and effective .
Thursday, August 26, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST This webcast will explore the benchmark practices for rapid progression from first-in-human to large-scale commercial manufacture for microdosing API. Micro-dosing at a commercial scale made effortless.
Monday, August 23, 2021 at 2pm EDT | 1pm CDT | 11am PDT What do Plato, Roombas, and digital twins for pharma manufacturing have in common? Learn how digital twins, powered by artificial intellingence, can reproduce conditions happening in physical assets to identify and optimize manufacturing process variables, predict outcomes, and empower to bio/pharma companies take action.
Friday, August 13, 2021 at 11am EDT| 8am PDT| 4pm BST|5pm CEST
Thursday, August 5, 2021 at 11am EDT| 8am PDT| 4pm BST|5pm CEST
Thursday, July 22, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST Local delivery of monoclonal antibodies to the lung is enabled by spray drying to manufacture stable, respirable dry powders. An inhaled formulation of bevacizumab was effective in vivo, reducing tumor burden in a rat model of non-small cell lung cancer.
Wednesday, July 21, 2021 This Technology Forum will explore the current state of commercialization for cell and gene therapies and the patient and physician perspective, as well as the need for technologies, processes, and strategies to ensure competent delivery of these treatments to patients.